Item 5.07 Submission of Matters to a Vote of Security Holders.
On September 21, 2020, the OWC Pharmaceutical Research Corp. (the "Company")
held the continuation of a special meeting of stockholders that was scheduled
for August 31, 2020 and was adjourned to September 14, 2020 and to September 21,
2020 (the "Meeting") for stockholders to vote on the following proposals: (i) to
authorize the Company's Board of Directors to effect one reverse stock split of
the Company's outstanding Common Stock, $0.00001 par value per share, at any
ratio between 1-for-10 and 1-for-20 at such time as the Company's Board of
Directors shall determine, in its sole discretion, before seven (7) days after
the closing of the Meeting ("Proposal No. 1"); (ii) to amend the Company's
Certificate of Incorporation, as amended to increase the number of the Company's
authorized shares of Common Stock from 500,000,000 shares to 2,500,000,000
shares ("Proposal No. 2"); and (iii) to approve one or more adjournments to the
Meeting, if necessary or appropriate, to permit further solicitation of proxies
if there are not sufficient votes at the time of the Meeting cast in favor of
Proposals No. 1 and/or No. 2 ("Proposal No. 3").
As of August 4, 2020, (the "Record Date") for the Meeting, there were
497,498,338 shares of the Company's Common Stock issued and outstanding and
entitled to vote with one vote per share on each proposal, 381 shares of the
Company's Series A Preferred Stock, which entitled the holders thereof to an
aggregate of 24,825,167 votes and 43,675 shares of the Company's Series B
Preferred Stock issued and outstanding and were entitled to an aggregate of
43,675,000 votes.
In order to conduct the business of the Meeting, the Company required the
presence, in person or by proxy, of a quorum consisting of a majority of the
outstanding shares of stock entitled to vote as of the Record Date. Quorum was
present at the Meeting, and the Company's stockholders approved a further
adjournment of the Meeting to October 28, 2020 (the "Adjournment Date"), to
allow additional time for stockholders to vote and seek approval for Proposals
No. 1 and 2.
The vote results for Proposal 3, the only proposal that had an effect at the
Meeting were as follows:
Votes For Votes Against Abstentions
155,880,704 110,805,564 19,550,190
The Company will amend this Current Report on Form 8-K to report the results of
the vote on Proposals 1 and 2 following the Adjournment Date.
© Edgar Online, source Glimpses
OWC PHARMACEUTICAL RESEARCH CORP. 
